Entering a new pharmaceutical market involves more than securing marketing authorisation. Companies must understand local regulatory requirements, prepare the right documentation, establish appropriate representation and align approval timelines with commercial plans. Israel is no exception.
For foreign pharmaceutical manufacturers, Israel offers a structured regulatory environment overseen by the Ministry of Health (MOH). Changes introduced in 2025 also created opportunities for eligible medicines to benefit from shorter registration evaluation periods through reliance on assessments conducted by recognised foreign regulatory authorities.
However, a successful pharmaceutical launch in Israel depends on more than selecting the fastest available route. Companies need to assess product eligibility, confirm local requirements, plan for pricing and reimbursement, and establish processes for ongoing compliance.
A well-defined strategy for drug registration in Israel helps companies identify regulatory dependencies early, reduce avoidable submission gaps and coordinate registration with the wider requirements of market entry.
Understanding Israel's Pharmaceutical Regulatory Framework
Israel’s Ministry of Health, primarily through its Pharmaceutical Division, oversees the registration of medicinal products. Under Section 47 of the Pharmacists Ordinance and the Pharmacists Regulations (Preparations), 1986, medicines generally must be registered in the Israeli Drug Registry before they can be manufactured, imported or marketed, subject to applicable legal exceptions.
The registration process assesses whether a medicine meets the relevant requirements for quality, safety and efficacy. Depending on the product and application route, the review may involve administrative and product information, manufacturing and quality documentation, nonclinical and clinical evidence, and supporting certificates.
Israel also takes account of certain foreign regulatory strategies approvals under specified conditions. This can be particularly relevant for companies that already hold authorisations in established markets. However, foreign approval does not automatically grant permission to market a product in Israel.
Companies must distinguish between three separate milestones:
- Regulatory registration: Obtaining the applicable Israeli marketing authorisation.
- Commercial access: Addressing applicable pricing, reimbursement and market-access considerations.
- Operational readiness: Establishing the necessary importation, distribution, supply and post-approval compliance arrangements.
These activities are related, but they are not interchangeable. Planning them together helps prevent a situation in which a product receives regulatory approval but is not ready for commercial launch.
Who Can Register a Medicine in Israel? Requirements for Foreign Companies
Foreign pharmaceutical manufacturers can pursue registration in Israel through the arrangements permitted by the MOH. The Ministry’s published application guidance identifies Israeli representatives of manufacturers and rights owners located abroad among the eligible applicant categories.
The application must be submitted by a pharmacist authorised by the Ministry of Health. Foreign companies should therefore establish the appropriate applicant and representation arrangements before beginning submission preparation.
Key considerations include:
- Applicant eligibility: Confirm the appropriate applicant structure and the role of the overseas rights owner or Israeli representative.
- Authorised submission: Ensure that the application is prepared and submitted through the required authorised pharmacist.
- Product ownership and supporting evidence: Establish that the necessary authorisations, product details and supporting documents are available.
- Manufacturing and quality compliance: Verify the relevant manufacturing information, quality documentation and certificates required for the proposed registration route.
- Local product information: Assess the applicable Israeli requirements for product information, labelling services and patient-facing materials.
- Ongoing responsibilities: Allocate accountability for regulatory correspondence, variations, renewals and pharmacovigilance.
These requirements should be assessed against the applicable product-specific procedure rather than treated as a single checklist that applies identically to every medicine. For companies without an established Israeli regulatory presence, resolving these arrangements early can help avoid administrative gaps and unclear responsibilities during submission and after approval.
Choosing the right Israeli Drug Registration Pathway
The appropriate registration pathway depends on the medicine’s classification, existing foreign approvals, supporting documentation and eligibility under the applicable Israeli procedure.
The first step is to assess the product’s current regulatory status. A company with an approved original medicine may have different options from a manufacturer registering a biosimilar or generic medicine. The availability of a reliance-based route may also depend on when the reference authority granted approval and whether the proposed Israeli application satisfies the relevant conditions.
A structured pathway assessment should establish:
- Whether the product is an original medicine, biosimilar or generic medicine.
- Which foreign regulatory authorities have approved it.
- Whether the approvals meet the applicable timing and recognition criteria.
- Whether the proposed Israeli application is sufficiently aligned with the reference-authority dossier.
- Whether additional local documentation, quality assessment or other regulatory requirements apply.
- Whether a standard registration procedure or another applicable route is more appropriate.
Regulatory reliance is not automatic mutual recognition. The Israeli authority retains its regulatory responsibilities and makes decisions under the applicable Israeli framework. A previous approval can therefore support a registration strategy without removing the need to demonstrate eligibility and comply with local requirements.
For portfolios containing several products, evaluating pathways individually can also help companies prioritise submissions and allocate regulatory resources more effectively.
Israel's 2025 Drug Registration Reform: 70-Day and 120-Day Routes Explained
On 25 March 2025, Israel’s Ministry of Health announced a reform intended to streamline medicine registration by making greater use of assessments conducted by recognised foreign regulatory authorities. The framework took effect in late March 2025 as a regulatory pilot for 2025–2026.
The reform introduced reliance-based tracks with stated evaluation periods of 70 or 120 working days for eligible products. These periods are conditional on meeting the applicable requirements; they are not universal registration deadlines.
- Reliance Track A: 70 working days
This track was introduced for qualifying original medicines and biosimilars. The published framework describes eligibility based on registration by at least two recognised foreign regulatory authorities within the preceding three years. - Reliance Track B: 120 working days
This track was introduced for qualifying original medicines and biosimilars with the required approval from one recognised foreign regulatory authority within the preceding five years. - Reliance Track C: 120 working days
This route applies to qualifying generic medicines based on innovative medicines already registered in Israel, subject to the applicable eligibility criteria. The published reform summary specifies that the generic medicine must also have received approval from at least one recognised regulatory authority within the preceding three years. Eligibility should be checked against the current Ministry of Health requirements before submission.
The recognised-authority list, qualifying approval dates, product definitions and dossier requirements must be checked against the applicable MOH procedure. The published framework has included authorities such as the US Food and Drug Administration (FDA), European Medicines Agency (EMA), UK Medicines and Healthcare products Regulatory Agency (MHRA), Health Canada and Australia’s Therapeutic Goods Administration (TGA), but companies should not assume that every authority or combination qualifies for every track.
The stated evaluation periods refer to the relevant regulatory process, not the entire period from initial planning to commercial launch. Dossier preparation, eligibility checks, additional-information requests and commercial activities may affect the overall schedule.
What the reform means for launch planning
The principal benefit is the potential to reduce duplicated assessment work for eligible products. To determine whether that benefit is available, companies should verify the current procedure, assess their reference approvals and compare the proposed Israeli submission with the dossier relied upon. Because the framework was introduced as a 2025–2026 pilot, its status and any subsequent amendments should be confirmed with the MOH before a submission is planned in late 2026 or later. A shortened evaluation period should only be used in a launch forecast after eligibility and the applicable procedural requirements have been established.
What Documents Are Required for Pharmaceutical Registration in Israel?
The documentation required for drug registration in Israel varies according to the product, application type and registration pathway.
The MOH’s published application guidance describes a dossier structure covering administrative and product information, nonclinical and clinical evidence, scientific summaries and comparative bioavailability information where relevant. The exact content should be determined from the applicable registration procedure.
A typical documentation assessment covers the following areas:
- Administrative and legal documentation
- Application forms and declarations.
- Details of the applicant, rights owner and relevant manufacturers.
- Supporting authorisations and certificates.
- Evidence of qualifying foreign approvals, where applicable.
- Quality and manufacturing documentation
- Active substance and finished-product quality information.
- Manufacturing processes, sites and controls.
- Specifications and analytical methods.
- Stability data, shelf life and storage conditions.
- Applicable GMP and quality certification documentation.
- Nonclinical and clinical evidence
- Relevant nonclinical and clinical study data.
- Safety and efficacy evidence.
- Scientific summaries and supporting references.
- Bioavailability or bioequivalence documentation where required.
- Product information and risk management
- Proposed product information and labelling.
- Patient and professional information, as applicable.
- Relevant safety and risk-management documentation.
- Other product-specific supporting materials required by the applicable procedure.
For a reliance-based application, dossier consistency deserves particular attention. Differences in indications, dosage regimens, formulation, manufacturing information or product documentation may affect eligibility or trigger additional regulatory work, depending on the applicable route. A pre-submission gap analysis can help identify missing documents, inconsistent product information and outstanding quality requirements before the application is filed.
How Long Does Drug Registration Take in Israel?
The time required for registration depends on the applicable pathway, product eligibility, dossier readiness and the regulatory review process.
Under the 2025 reform, eligible products could use routes with stated evaluation periods of 70 or 120 working days. These figures should not be treated as a general estimate for every medicine or as a guarantee of approval within that period. The applicable procedure and its status must first be confirmed. Companies should plan for the complete drug registration process in India rather than relying solely on the formal evaluation period.
| Planning Stage | Key Activity |
|---|---|
| Regulatory Assessment | Confirm the product category and applicable registration route. |
| Dossier Preparation | Assemble the required administrative, quality, clinical and product information. |
| Local Readiness | Resolve applicant arrangements and other applicable local requirements. |
| Regulatory Evaluation | Allow for the relevant review period and any requests for additional information. |
| Commercial Preparation | Coordinate pricing, reimbursement, importation, distribution and supply planning. |
| Post-Approval Readiness | Establish procedures for safety reporting, variations, renewals and ongoing compliance. |
Some activities can proceed in parallel, depending on the product and the company’s operating model. Others depend on regulatory decisions or specific permissions. A product-specific timeline should therefore identify the critical path, outstanding dependencies and activities that could delay commercial availability. This provides a more reliable basis for launch decisions than a headline review period alone.
Pricing, Reimbursement and the Israeli Health Basket
Regulatory registration is only one part of pharmaceutical market access in Israel. A medicine’s approval does not automatically establish its final commercial price, secure public reimbursement or guarantee inclusion in the National Health Basket.
Prescription medicines are subject to applicable price-control arrangements. Companies should determine the rules relevant to their product and commercial model, including any requirements affecting the proposed price and distribution arrangements.
Inclusion in the National Health Basket is a separate decision-making process. Considerations can include clinical benefit, unmet medical need, comparative effectiveness, the available evidence and budgetary impact. Inclusion should not be assumed as an automatic consequence of registration.
For foreign pharmaceutical manufacturers, early market-access planning should address:
- Pricing requirements: Determine the applicable price-control rules and their implications for commercial forecasts.
- Reimbursement strategy: Establish whether public reimbursement is a priority and identify the relevant decision-making process.
- Evidence requirements: Assess the clinical, comparative and health-economic evidence needed to support the product’s value proposition.
- Commercial scenarios: Model potential access and revenue scenarios without assuming that registration guarantees reimbursement.
- Supply and distribution: Align operational planning with the anticipated market-access strategy and expected demand.
The timing of pricing and reimbursement activities should be considered alongside regulatory planning, while recognising that the processes have different requirements and decision points.
A coordinated strategy helps companies make more realistic launch assumptions and identify commercial dependencies before committing to a launch date.
Post-Approval Responsibilities: Renewals, Variations and Pharmacovigilance
Obtaining registration does not end a company’s regulatory obligations. Maintaining the authorised status of a medicine requires ongoing oversight of product information, quality documentation, safety requirements and changes to the registered product.
- Renewals
The MOH’s published guidance states that a drug registration certificate is initially granted for five years. Renewal extends the registration validity for a further ten years, subject to the applicable requirements.
The Ministry’s guidance specifies that the quality certification application should be submitted nine months before the registration expires, while the drug registration renewal application should be submitted no later than 30 days before expiry. Companies should verify the current procedural requirements and allow sufficient time to address outstanding documentation. - Variations and product changes
Changes to a registered medicine must be assessed under the applicable Israeli procedure. Relevant changes may include the registration owner’s details, manufacturer or manufacturing location, labelling, expiry information, product composition and other authorised particulars.
The regulatory impact should be assessed before implementation. Companies need to determine whether a change requires an application, notification or other action and whether approval is required before the change can take effect. - Pharmacovigilance
Marketing authorization holders must comply with applicable Israeli pharmacovigilance requirements. Depending on the product and circumstances, these may include adverse-event reporting, safety-data management, signal assessment and risk-management activities.
Companies should establish clear responsibilities for receiving and processing safety information, meeting reporting timelines, maintaining relevant records and coordinating local obligations with their global pharmacovigilance services.
Lifecycle management
A central regulatory tracking process can help companies monitor renewals, variations, safety updates and changes to approved product information. This is particularly important for organisations managing multiple products or markets, where a change in one jurisdiction may require an assessment of its impact on Israeli registration. Effective lifecycle management supports continued compliance after the initial launch and helps prevent avoidable administrative gaps.
Foreign Company Launch Checklist for Israel
Before finalising a launch plan, foreign pharmaceutical manufacturers should assess the regulatory, operational and commercial dependencies associated with their product.
| Phase | Combined Regulatory Component | Consolidated Focus & Actions |
|---|---|---|
| Phase 1: Strategy & Setup | Product Profile & Pathway Strategy | Confirm category, indications, and foreign approvals. Select optimal path (e.g., 70/120-day route) and set up local representation and pharmacist structures. |
| Phase 2: Technical Dossier | Dossier Readiness & Global Alignment | Identify data gaps across CMC, clinical, and admin files. Align dossier consistency with manufacturing compliance and reference country approvals. |
| Phase 3: Local Customization | Commercial & Local Compliance | Adapt labeling to Israeli rules. Finalize pricing, reimbursement plans, and operational setup for import and distribution. |
| Phase 4: Operations & Growth | Timeline Planning & Lifecycle Oversight | Map out timelines from filing to commercial launch. Set up pharmacovigilance tracking and assign ownership for variations and renewals. |
Completing this assessment before submission helps companies identify dependencies while there is still time to address them. It also creates a clearer basis for coordinating regulatory milestones with commercial launch decisions.
How DDReg Supports Pharmaceutical Market Entry in Israel
Entering a new market requires decisions that connect regulatory requirements with the realities of dossier preparation, local compliance and commercial planning. DDReg’s regulatory affairs services in Israel can support pharmaceutical and biotechnology companies in assessing these requirements and planning their registration activities.
Depending on the product and project scope, support may include:
- Regulatory strategy and pathway assessment: Reviewing existing authorisations, assessing potential eligibility for applicable Israeli registration routes and identifying the regulatory requirements that need to be addressed.
- Dossier gap analysis and preparation: Evaluating available documentation, identifying country-specific gaps and coordinating the preparation of the submission in line with the applicable requirements.
- Submission planning and regulatory coordination: Supporting document management, eCTD submission readiness, regulatory correspondence and responses to authority questions.
- Regulatory intelligence: Monitoring relevant regulatory developments and assessing their potential impact on registration strategy, product information and compliance planning.
- Post-approval lifecycle management: Supporting the coordination of renewals, variations and other regulatory activities required to maintain the authorised status of a medicine.
- Pharmacovigilance support: Helping companies assess applicable product-safety obligations and coordinate relevant activities with their pharmacovigilance framework.
Explore DDReg’s Regulatory Affairs Services in Israel to learn more about the available support or visit DDReg Pharma to discuss your regulatory requirements.
Conclusion
A successful pharmaceutical launch in Israel requires a strategy that extends beyond registration. Companies need to establish the appropriate applicant arrangements, select a suitable regulatory pathway, prepare a consistent dossier and plan for pricing, reimbursement, distribution and post-approval compliance.
Israel’s 2025 drug registration reform introduced potentially shorter evaluation periods for eligible medicines. However, the benefits depend on the applicable criteria, the quality and consistency of the submission, and the status of the relevant procedure.
For foreign pharmaceutical manufacturers, the most effective approach is to assess these requirements early and coordinate regulatory planning with commercial readiness. With a clear understanding of local obligations and appropriate regulatory support, companies can make better-informed decisions and establish a more sustainable route into the Israeli pharmaceutical market.
Frequently Asked Questions
No. Approval from the US Food and Drug Administration (FDA) or European Medicines Agency (EMA) does not automatically authorise a medicine for marketing in Israel. However, qualifying foreign approvals may support eligibility for a reliance-based registration pathway, subject to the applicable Israeli Ministry of Health (MOH) requirements, product eligibility criteria and supporting documentation.
Israel introduced reliance-based registration pathways in 2025 with stated evaluation periods of 70 or 120 working days for eligible medicines. The applicable route depends on the product category, qualifying foreign approvals and specific eligibility conditions. These periods are not guaranteed approval timelines, and companies should verify the latest MOH procedure before submission.
Documentation requirements depend on the product and registration pathway. They may include administrative forms, foreign approval evidence, manufacturing and quality documentation, nonclinical and clinical data, product information, labelling, and bioavailability or bioequivalence evidence where applicable. A pre-submission gap analysis helps identify missing documents and country-specific requirements.
No. Marketing authorisation and reimbursement are separate processes. Registration permits marketing subject to the applicable requirements, but it does not guarantee inclusion in Israel's National Health Basket. Companies should assess applicable medicine pricing rules, reimbursement requirements and the evidence needed to support market access as part of their launch strategy.